Advertisement

Surgery pp 1211-1228 | Cite as

Thyroid

  • Ronald J. Weigel

Abstract

The common indications for thyroidectomy include a suspicion of cancer, local symptoms of a large neck mass (e.g., difficulty breathing or swallowing), and abnormal thyroid function (e.g., hyperthyroidism). Surgical management of thyroid problems requires a thorough understanding of the anatomy and pathophysiology of the thyroid gland.

Keywords

Thyroid Cancer Thyroid Carcinoma Papillary Thyroid Carcinoma Thyroid Nodule Total Thyroidectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tietgens ST, Leinung MC. Thyroid storm. Med Clin North Am 1995;79:169–184.PubMedGoogle Scholar
  2. 2.
    Yoshida D. Thyroid storm precipitated by trauma. J Emerg Med 1996;14:697–701.PubMedCrossRefGoogle Scholar
  3. 3.
    Brown RS. Editorial: Immunoglobulins affecting thyroid growth: a continuing controversy. J Clin Endocrinol Metab 1996;80:1506–1508.Google Scholar
  4. 5.
    Razack MS, Lore JM, Lippes HA, Schaefer DP, Rassael H. Total thyroidectomy for Graves’ disease. Head Neck 1997;19:378–383.PubMedCrossRefGoogle Scholar
  5. 6.
    Linos DA, Karakitsos D, Pappademetriou J. Should the primary treatment of hyperthyroidism be surgical? Eur J Surg 1997;163:651–657.PubMedGoogle Scholar
  6. 7.
    Gerenova J, Buysschaert M, de Burbure CY, Daumerie C. Prevalence of thyroid cancer in Graves’ disease: a retrospective study of a cohort of 103 patients treated surgically. Eur J Intern Med 2003;14:321–325.PubMedCrossRefGoogle Scholar
  7. 8.
    Belfiore A, Garofalo MR, Giuffrida D, et al. Increased aggressiveness of thyroid cancer in patients with Graves’ disease. J Clin Endocrinol Metab 1990;70:830–835.PubMedGoogle Scholar
  8. 9.
    Joseph UA, Jhingran SG. Graves’ disease and concurrent thyroid carcinoma: the importance of thyroid scintigraphy in Graves’ disease. Clin Nucl Med 1995;20:416–418.PubMedGoogle Scholar
  9. 10.
    Levy EG. Treatment of Graves’ disease: the American way. Bailliere’s Clin Endocrinol Metab 1997;11:585–595.CrossRefGoogle Scholar
  10. 11.
    American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002;8:457–469.Google Scholar
  11. 12.
    Witte J, Goretzki PE, Roher HD. Surgery for Graves disease in childhood and adolescence. Exp Clin Endocrinol Diabetes 1997;105:58–60.PubMedGoogle Scholar
  12. 13.
    Miccoli P, Vitti P, Rago T, et al. Surgical treatment of Graves’ disease: subtotal or total thyroidectomy? Surgery (St. Louis) 1996;11:1020–1025.CrossRefGoogle Scholar
  13. 14.
    Torring O, Tallstedt L, Wallin G, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine—a prospective, randomized study. J Clin Endocrinol Metab 1996;81:2986–2993.PubMedCrossRefGoogle Scholar
  14. 15.
    Rudberg C, Johansson H, Akerstrom G, Tuvemo T, Karlsson FA. Graves’ disease in children and adolescents. Late results of surgical treatment. Eur J Endocrinol 1996;134:710–215.PubMedCrossRefGoogle Scholar
  15. 16.
    Chi SY, Hsei KC, Sheen-Chen SM, Chou FF. A prospective randomized comparison of bilateral subtotal thyroidectomy versus unilateral total and contralateral subtotal thyroidectomy for Graves’ disease. World J Surg 2005;18:18.Google Scholar
  16. 17.
    Sugino K, Mimura T, Ozaki O, et al. Management of recurrent hyperthyroidism in patients with Graves’ disease treated by subtotal thyroidectomy. J Endocrinol Invest 1995;18:415–419.PubMedGoogle Scholar
  17. 18.
    Abe Y, Sato H, Noguchi M, et al. Effect of subtotal thyroidectomy on natural history of ophthalmopathy in Graves’ disease. World J Surg 1998;22:714–717.PubMedCrossRefGoogle Scholar
  18. 19.
    Berti P, Materazzi G, Galleri D, Donatini G, Minuto M, Miccoli P. Video-assisted thyroidectomy for Graves’ disease: report of a preliminary experience. Surg Endosc 2004;18:1208–1210.PubMedCrossRefGoogle Scholar
  19. 20.
    Siegel RD, Lee SL. Toxic nodular goiter. Endocrinol Metab Clin NAm 1998;27:151–168.CrossRefGoogle Scholar
  20. 21.
    Erickson D, Gharib H, Li H, vanHeerden JA. Treatment of patients with toxic multinodular goiter. Thyroid 1998;8:277–282.PubMedGoogle Scholar
  21. 22.
    David E, Rosen IB, Bain J, James J, Kirsh JC. Management of the hot thyroid nodule. Am J Surg 1995;170:481–483.PubMedCrossRefGoogle Scholar
  22. 23.
    Rojdmark J, Jarhult J. High long term recurrence rate after subtotal thyroidectomy for nodular goitre. Eur J Surg 1995;161:725.PubMedGoogle Scholar
  23. 24.
    Seiler CA, Glaser C, Wagner HE. Thyroid gland surgery in an endemic region. World J Surg 1996;20:593–597.PubMedCrossRefGoogle Scholar
  24. 25.
    Mack E. Management of patients with substernal goiters. Endocr Surg 1995;75:377–394.Google Scholar
  25. 26.
    Newman E, Shaha AR. Substernal goiter. J Surg Oncol 1995;60:207–212.PubMedCrossRefGoogle Scholar
  26. 27.
    Alio MD, Thompson NW. Rationale for the operative management of substernal goiters. Surgery (St. Louis) 1983;94:969–977.Google Scholar
  27. 28.
    Torre G, Borgonovo G, Amato A, et al. Surgical management of substernal goiter: analysis of 237 patients. Am Surg 1995;61:826–831.PubMedGoogle Scholar
  28. 29.
    Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993;328:553–559.PubMedCrossRefGoogle Scholar
  29. 30.
    Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Intern Med 1996;156:2165–2172.PubMedCrossRefGoogle Scholar
  30. 31.
    Sabel MS, Staren ED, Gianakakis LM, Dwarakanathan S, Prinz RA. Effectiveness of the thyroid scan in evaluation of the solitary thyroid nodule. Am Surg 1997;63:660–664.PubMedGoogle Scholar
  31. 32.
    Agrawal S. Diagnostic accuracy and role of fine needle aspiration cytology in management of thyroid nodules. J Surg Oncol 1995;58:168–172.PubMedCrossRefGoogle Scholar
  32. 33.
    Woeber KA. Cost-effective evaluation of the patient with a thyroid nodule. Endocr Surg 1995;75:357–363.Google Scholar
  33. 34.
    Carmeci C, Jeffrey RB, McDougall IR, Nowels KW, Weigel RJ. Ultrasound-guided fine-needle aspiration biopsy of thyroid masses. Thyroid 1998;8:283–289.PubMedGoogle Scholar
  34. 35.
    Rodriquez JM, Parrilla P, Sola S, et al. Comparison between preoperative cytology and intraoperative frozen-section biopsy in the diagnosis of thyroid nodules. Br J Surg 1994;81:1151–1154.CrossRefGoogle Scholar
  35. 36.
    Chen H, Zeiger MA, Clark DP, Westra WH, Udelsman R. Papillary carcinoma of the thyroid: can operative management be based solely on fine-needle aspiration? J Am Coll Surg 1997;184:605–610.PubMedGoogle Scholar
  36. 37.
    Aguilar-Diosdado M, Contreras A, Gavilan I, et al. Thyroid nodules: role of fine needle aspiration and intraoperative frozen section examination. Acta Cytol 1997;41:677–682.PubMedGoogle Scholar
  37. 38.
    Chen H, Nicol TL, Udelsman R. Follicular lesions of the thyroid: does frozen section evaluation alter operative management? Ann Surg 1995;222:101–106.PubMedCrossRefGoogle Scholar
  38. 39.
    McHenry CR, Raeburn C, Strickland T, Marty JJ. The utility of routine frozen section examination for intraoperative diagnosis of thyroid cancer. Am J Surg 1996;172:658–661.PubMedCrossRefGoogle Scholar
  39. 40.
    Hamming JF, Vriens MR, Goslings BM, Songun I, Fleuren GJ, VanDeVelde CJH. Role of fine-needle aspiration biopsy and frozen section examination in determining the extent of thyroidectomy. World J Surg 1998;22:575–580.PubMedCrossRefGoogle Scholar
  40. 41.
    Rios Zambudio A, Rodriguez Gonzalez JM, Sola Perez J, et al. Utility of frozen-section examination for diagnosis of malignancy associated with multinodular goiter. Thyroid 2004;14:600–604.PubMedCrossRefGoogle Scholar
  41. 42.
    Calicut RA, Selvaggi SM, Mack E, Ozgul O, Warner T, Chen H. The utility of frozen section evaluation for follicular thyroid lesions. Ann Surg Oncol 2004;11:94–98.CrossRefGoogle Scholar
  42. 43.
    Tyler DS, Winchester DJ, Caraway NP, Hickey RC, Evans DB. Indeterminate fine-needle aspiration biopsy of the thyroid: identification of subgroups at high risk for invasive carcinoma. Surgery (St. Louis) 1994;116:1054–1060.PubMedGoogle Scholar
  43. 44.
    Chen H, Nicol TL, Zeiger MA, et al. Hurthle cell neoplasms of the thyroid. Ann Surg 1998;227:542–546.PubMedCrossRefGoogle Scholar
  44. 45.
    Paphavasit A, Thompson GB, Hay ID, et al. Follicular and Hurthle cell thyroid neoplasms. Arch Surg 1997;132:674–679.PubMedGoogle Scholar
  45. 46.
    Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6–30.PubMedCrossRefGoogle Scholar
  46. 47.
    Doniach I. Carcinogenic effect of 100, 250 and 500 rad x-rays on the rat thyroid gland. Br J Cancer 1974;30:487–495.PubMedGoogle Scholar
  47. 48.
    Fraker DL. Radiation exposure and other factors that predispose to human thyroid neoplasia. Endocr Surg 1995;75:365–375.Google Scholar
  48. 49.
    Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin’s disease. N Engl J Med 1991;325:599–605.PubMedGoogle Scholar
  49. 50.
    Shore RE, Hildreth N, Dvoretsky P, Andresen E, Moseson M, Pasternack B. Thyroid cancer among persons given x-ray treatment in infancy for an enlarged thymus gland. Am J Epidemiol 1993;137:1068–1080.PubMedGoogle Scholar
  50. 51.
    Ron E, Modan B, Preston D, et al. Thyroid neoplasias following low-dose radiation in childhood. Radiat Res 1989;120:516–531.PubMedCrossRefGoogle Scholar
  51. 52.
    Nagataki S, Shibata Y, Inoue S, Yokoyama N, Izumi M, Shimaoka K. Thyroid diseases among atomic bomb survivors in Nagasaki. JAMA 1994;272:384–370.CrossRefGoogle Scholar
  52. 53.
    Doniach I. Experimental induction of tumours of the thyroid by radiation. Br Med J 1958;14:181–183.Google Scholar
  53. 54.
    McDougall LR, ed. Thyroid Disease in Clinical Practice. London: Chapman & Hall, 1992:304–324.Google Scholar
  54. 55.
    Tezelman S, Grossman RF, Siperstein AE, Clark OH. Radioiodine-associated thyroid cancers. World J Surg 1994;18:522–528.PubMedCrossRefGoogle Scholar
  55. 56.
    Holm L-E, Hall P, Wiklund K, et al. Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst 1991;83:1072–1077.PubMedCrossRefGoogle Scholar
  56. 57.
    Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab 1974;38:976–998.PubMedCrossRefGoogle Scholar
  57. 58.
    Smith WG, Kern BB. The nature of the mutation in familial multiple polyposis: papillary carcinoma of the thyroid, brain tumors, and familial multiple polyposis. Dis Colon Rectum 1973;16:264–271.PubMedCrossRefGoogle Scholar
  58. 59.
    Zeki K, Spambalg D, Sharifi N, Gonsky R, Fagin JA. Mutations of the adenomatous polyposis coli gene in sporadic thyroid neoplasms. J Clin Endocrinol Metab 1994;79:1317–1321.PubMedCrossRefGoogle Scholar
  59. 60.
    Grossman RF, Tu S-H, Duh Q-Y, Siperstein AE, Novosolov F, Clark OH. Familial nonmedullary thyroid cancer. Arch Surg 1995;130:892–897.PubMedGoogle Scholar
  60. 61.
    McKay JD, Lesueur F, Jonard L, et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet 2001;69:440–446.PubMedCrossRefGoogle Scholar
  61. 62.
    Mulligan LM, Kwok JBJ, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature (Lond) 1993;363:458–460.PubMedCrossRefGoogle Scholar
  62. 63.
    Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851–856.PubMedCrossRefGoogle Scholar
  63. 64.
    Eng C, Smith DP, Mulligan LM, et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 1994;3:237–241.PubMedCrossRefGoogle Scholar
  64. 65.
    Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype of MEN 2A and FMTC. Nat Genet 1994;6:70–74.PubMedCrossRefGoogle Scholar
  65. 66.
    Santoro M, Carlomagno F, Hay ID, et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 1992;89:1517–1522.PubMedCrossRefGoogle Scholar
  66. 67.
    Pierotti MA, Santoro M, Jenkins RB, et al. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PET. Med Sci 1992;89:1616–1620.Google Scholar
  67. 68.
    Tong Q, Li Y, Smanik PA, Fithian LJ, Xing S, Mazzaferri EL, Jhiang SM. Characterization of the promoter region and oligomerization domain of H4 (D10S170), a gene frequently rearranged with the ret proto-oncogene. Oncogene 1995;10:1781–1787.PubMedGoogle Scholar
  68. 69.
    Sozzi G, Bongarzone I, Miozzo M, et al. A t(10;17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma. Genes Chromosomes Cancer 1994;9:244–250.PubMedCrossRefGoogle Scholar
  69. 70.
    Bongarzone I, Butti MG, Coronelli S, et al. Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res 1994;54:2979–2985.PubMedGoogle Scholar
  70. 71.
    Teyssier J-R, Liautaud-Roger F, Ferre D, Patey M, Dufer J. Chromosomal changes in thyroid tumors: relation with DNA content, karyotypic features, and clinical data. Cancer Genet Cytogenet 1990;50:249–263.PubMedCrossRefGoogle Scholar
  71. 72.
    Beige G, Thode B, Bullerdiek J, Bartnitzke S. Aberrations of chromosome 19. Cancer Genet Cytogenet 1992;60:23–26.CrossRefGoogle Scholar
  72. 73.
    DalCin P, Sneyers W, Aly MS, et al. Involvement of 19q13 in follicular thyroid adenoma. Cancer Genet Cytogenet 1992;60:99–101.CrossRefGoogle Scholar
  73. 74.
    Farid NR, Shi Y, Zou M. Molecular basis of thyroid cancer. Endocr Rev 1994;15:202–232.PubMedGoogle Scholar
  74. 75.
    Hara H, Fulton N, Yashiro T, Ito K, DeGroot LJ, Kaplan EL. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery (St. Louis) 1994;116:1010–1016.PubMedGoogle Scholar
  75. 76.
    Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 1990;4:1474–1479.PubMedCrossRefGoogle Scholar
  76. 77.
    Simon D, Goretzki PE, Gorelev V, et al. Significance of p53 in human thyroid tumors. World J Surg 1994;18:535–541.PubMedCrossRefGoogle Scholar
  77. 78.
    Matias-Guiu X, Cuatrecasas M, Musulen E, Prat J. p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas. J Clin Pathol 1994;47:337–339.PubMedCrossRefGoogle Scholar
  78. 79.
    Nishida T, Nakao K, Hamaji M, Nakahara M-A, Tsujimoto M. Overexpression of p53 protein and DNA content are important biologic prognostic factors for thyroid cancer. Surgery (St. Louis) 1996;119:568–575.PubMedCrossRefGoogle Scholar
  79. 80.
    Grebe SKG, Hay ID. Follicular thyroid cancer. Endocrinol Metab Clin N Am 1995;24:761–801.Google Scholar
  80. 81.
    Martinez-Tello FJ, Martinez-Cabruja R, Fernandez-Martin J, Lasso-Oria C, Ballestin-Carcavilla C. Occult carcinoma of the thyroid. Cancer (Phila) 1993;71:4022–4029.PubMedCrossRefGoogle Scholar
  81. 82.
    Allo MD, Christianson W, Koivunen D. Not all “occult” papillary carcinomas are “minimal.” Surgery (St. Louis) 1988;104:971–976.PubMedGoogle Scholar
  82. 83.
    Patwardhan N, Cataldo T, Braverman LE. Surgical management of the patient with papillary cancer. Surg Clin N Am 1995;75:449–464.PubMedGoogle Scholar
  83. 84.
    Soh EY, Clark OH. Surgical considerations and approach to thyroid cancer. Endocrinol Metab Clin N Am 1996;25:115–139.CrossRefGoogle Scholar
  84. 85.
    Wong JB, Kaplan MM, Meyer K, Pauker SG. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. Endocrinol Metab Clin N Am 1990;19:741–760.Google Scholar
  85. 86.
    Stephenson BM, Wheeler MH, Clark OH. The role of total thyroidectomy in the management of differentiated thyroid cancer. Curr Opin Gen Surg 1994;53–59.Google Scholar
  86. 87.
    Harness JK, Thompson NW, McLeod MK, Pasieka JL, Fukuuchi A. Differentiated thyroid carcinoma in children and adolescents. World J Surg 1992;16:547–554.PubMedCrossRefGoogle Scholar
  87. 88.
    Hoelting T, Buhr HJ, Herfarth C. Intraoperative tumour classification in papillary thyroid cancer-a diagnostic dilemma. Eur J Surg Oncol 1995;21:353–356.PubMedCrossRefGoogle Scholar
  88. 89.
    Liu Q, Djuricin G, Prinz RA. Total thyroidectomy for benign thyroid disease. Surgery (St. Louis) 1998;123:2–7.PubMedGoogle Scholar
  89. 90.
    Burge MR, Zeise T-M, Johnsen MW, Conway MJ, Quails CR. Risks of complication following thyroidectomy. J Gen Intern Med 1998;13:24–31.PubMedCrossRefGoogle Scholar
  90. 91.
    Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery (St. Louis) 1988;104:947–953.PubMedGoogle Scholar
  91. 92.
    Nguyen KV, Dilawari RA. Predictive value of AMES scoring system in selection of extent of surgery in well differentiated carcinoma of thyroid. Am Surg 1995;61:151–155.PubMedGoogle Scholar
  92. 93.
    Shaha AR, Shah JP, Loree TR. Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol 1997;4:328–333.PubMedCrossRefGoogle Scholar
  93. 94.
    Sanders LE, Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg 1988;133:419–425.Google Scholar
  94. 95.
    Wanebo H, Coburn M, Teates D, Cole B. Total thyroidectomy does not enhance disease control or survival even in high-risk patients with differentiated thyroid cancer. Ann Surg 1998;227:912–921.PubMedCrossRefGoogle Scholar
  95. 96.
    Kim S, Wei JP, Braveman JM, Brams DM. Predicting outcome and directing therapy for papillary thyroid carcinoma. Arch Surg 2004;139:390–394;discussion 393–394.PubMedCrossRefGoogle Scholar
  96. 97.
    Kim ES, Kim TY, Koh JM, et al. Completion thyroidectomy in patients with thyroid cancer who initially underwent unilateral operation. Clin Endocrinol (Oxf) 2004;61:145–148.CrossRefGoogle Scholar
  97. 98.
    DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414–424.PubMedCrossRefGoogle Scholar
  98. 99.
    Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab 1992;75:714–720.PubMedCrossRefGoogle Scholar
  99. 100.
    Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418–428.PubMedCrossRefGoogle Scholar
  100. 101.
    Loh K-C, Greenspan FS, Gee L, Miller TR, Yeo PPB. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997;82:3553–3562.PubMedCrossRefGoogle Scholar
  101. 102.
    Weigel RJ. Advances in the diagnosis and management of well-differentiated thyroid cancers. Curr Opin Oncol 1996;8:37–43.PubMedCrossRefGoogle Scholar
  102. 103.
    Park HM, Park YH, Zhou XH. Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma. Thyroid 1997;7:277–280.PubMedCrossRefGoogle Scholar
  103. 104.
    McDougall IR. 74MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e., it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun 1997;18:505–512.PubMedGoogle Scholar
  104. 105.
    Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995;80:1488–1492.PubMedCrossRefGoogle Scholar
  105. 106.
    McDougall IR. 131I treatment of 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated? Thyroid 1997;7:669–672.PubMedCrossRefGoogle Scholar
  106. 107.
    Arad E, O’Mara RE, Wilson GA. Ablation of remaining functioning thyroid lobe with radioiodine after hemithyroidectomy for carcinoma. Clin Nucl Med 1993;18:662–663.PubMedCrossRefGoogle Scholar
  107. 108.
    Samuel AM, Rajashekharrao B. Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery. J Nucl Med 1994;35:1944–1950.PubMedGoogle Scholar
  108. 109.
    Hoyes KP, Owens SE, Millns MM, Allan E. Differentiated thyroid cancer: radioiodine following lobectomy—a clinical feasibility study. Nucl Med Commun 2004;25:245–251.PubMedCrossRefGoogle Scholar
  109. 110.
    Lin J-D, Kao P-F, Chao T-C. The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma. Br J Radiol 1998;71:307–313.PubMedGoogle Scholar
  110. 111.
    DiRusso G, Kern KA. Comparative analysis of complications from I-131 radioablation for well-differentiated thyroid cancer. Surgery (St. Louis) 1994;116:1024–1030.PubMedGoogle Scholar
  111. 112.
    Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med 1995;36:21–27.PubMedGoogle Scholar
  112. 113.
    Pacini F, Gasperi M, Fugazzola L, et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 1994;35:1418–1422.PubMedGoogle Scholar
  113. 114.
    Pacini F, Cetani F, Miccoli P, et al. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg 1994;18:600–604.PubMedCrossRefGoogle Scholar
  114. 115.
    McHenry C, Jarosz H, Davis M, Barbato AL, Lawrence AM, Paloyan E. Selective postoperative radioactive iodine treatment of thyroid carcinoma. Surgery (St. Louis) 1989;106:956–959.PubMedGoogle Scholar
  115. 116.
    Morris DM, Boyle PJ, Stidley CA, Altobelli KK, Parnell T, Key C. Localized well-differentiated thyroid carcinoma: survival analysis of prognostic factors and 131I therapy. Ann Surg Oncol 1998;5:329–337.PubMedCrossRefGoogle Scholar
  116. 117.
    Meier CA, Braverman LE, Ebner SA, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 1994;78:188–196.PubMedCrossRefGoogle Scholar
  117. 118.
    Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997;337:888–896.PubMedCrossRefGoogle Scholar
  118. 119.
    Newman KD, Black T, Heller G, et al. Differentiated thyroid cancer: determinants of disease progression in patients less than 21 years of age at diagnosis. Ann Surg 1998;227:533–541.PubMedCrossRefGoogle Scholar
  119. 120.
    Andersen PE, Kinsella J, Loree TR, Shaha AR, Shah JP. Differentiated carcinoma of the thyroid with extrathyroidal extension. Am J Surg 1995;170:467–470.PubMedCrossRefGoogle Scholar
  120. 121.
    Melliere DJM, Yahia NEB, Becquemin JP, Lange F, Boulahdour H. Thyroid carcinoma with tracheal or esophageal involvement: limited or maximal surgery? Surgery (St. Louis) 1993;113:166–172.PubMedGoogle Scholar
  121. 122.
    Ozaki O, Sugino K, Mimura T, Ito K. Surgery for patients with thyroid carcinoma invading the trachea: circumferential sleeve resection followed by end-to-end anastomosis. Surgery (St. Louis) 1995;117:268–271.PubMedCrossRefGoogle Scholar
  122. 123.
    Ballantyne AJ. Resections of the upper aerodigestive tract for locally invasive thyroid cancer. Am J Surg 1994;168:636–639.PubMedCrossRefGoogle Scholar
  123. 124.
    Scheumann GFW, Gimm O, Wegener G, Hundeshagen H, Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 1994;18:559–568.PubMedCrossRefGoogle Scholar
  124. 125.
    DeGroot LJ, Kaplan EL, Shukla MS, Salti G, Straus FH. Morbidity and mortality in follicular thyroid cancer. J Clin Endocrinol Metab 1995;80:2946–2953.PubMedCrossRefGoogle Scholar
  125. 126.
    Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297–305.PubMedCrossRefGoogle Scholar
  126. 127.
    Brennan MD, Bergstralh EJ, van Heerden JA, McConahey WM. Follicular thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 1991;66:11–22.PubMedGoogle Scholar
  127. 128.
    Grant CS. Operative and postoperative management of the patient with follicular and Hurthle cell carcinoma. Surg Clin N Am 1995;75:395–403.PubMedGoogle Scholar
  128. 129.
    Terry JH, St. John SA, Karkowski FJ, et al. Tall cell papillary thyroid cancer: incidence and prognosis. Am J Surg 1994;168:459–461.PubMedCrossRefGoogle Scholar
  129. 130.
    Moreno-Egea A, Rodriguez-Gonzalez JM, Sola-Perez J, Soria-Cogollos T, Parrilla-Paricio P. Multivariate analysis of histopathological features as prognostic factors in patients with papillary thyroid carcinoma. Br J Surg 1995;82:1092–1094.PubMedCrossRefGoogle Scholar
  130. 131.
    Segal K, Fridental R, Lubin E, Shvero J, Sulkes J, Feinmesser R. Papillary carcinoma of the thyroid. Otolaryngol Head Neck Surg 1995;113:356–363.PubMedCrossRefGoogle Scholar
  131. 132.
    Ruiz de Almodovar JM, Ruiz-Garcia J, Olea N, Villalobos M, Pedraza V. Analysis of risk of death from differentiated thyroid cancer. Radiother Oncol 1994;31:207–212.PubMedCrossRefGoogle Scholar
  132. 133.
    Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery (St. Louis) 1987;102:1088–1095.PubMedGoogle Scholar
  133. 134.
    Thyroid gland. In: Beahrs OH, Myers MH, eds. Manual for Staging of Cancer. Philadelphia: Lippincott, 1988:55–60.Google Scholar
  134. 135.
    Noguchi S, Murakami N, Kawamoto H. Classification of papillary cancer of the thyroid based on prognosis. World J Surg 1994;18:552–558.PubMedCrossRefGoogle Scholar
  135. 136.
    Ladenson PW. Optimal laboratory testing for diagnosis and monitoring of thyroid nodules, goiter, and thyroid cancer. Clin Chem 1996;42:183–187.PubMedGoogle Scholar
  136. 137.
    Ozata M, Suzuki S, Takahide M, et al. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994;79:98–105.PubMedCrossRefGoogle Scholar
  137. 138.
    Coburn M, Teates D, Wanebo H. Recurrent thyroid cancer. Ann Surg 1994;291:587–595.CrossRefGoogle Scholar
  138. 139.
    Desai D, Jeffrey RB, McDougall IR, Weigel RJ. Intraoperative ultrasonography for localization of recurrent thyroid cancer. Surgery (St. Louis) 2001;129:498–500.PubMedGoogle Scholar
  139. 140.
    Karwowski JK, Jeffrey RB, McDougall IR, Weigel RJ. Intraoperative ultrasonography improves identification of recurrent thyroid cancer. Surgery (St. Louis) 2002;132:924–928;discussion 928–929.PubMedCrossRefGoogle Scholar
  140. 141.
    Farahati J, Reiners C, Stuschke M, et al. Differentiated thyroid cancer: impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer (Phila) 1996;77:172–180.PubMedCrossRefGoogle Scholar
  141. 142.
    Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB. The effects of surgery, radio-iodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer (Phila) 1998;82:375–388.PubMedCrossRefGoogle Scholar
  142. 143.
    Moley JF. Medullary thyroid cancer. Surg Clin N Am 1995;75:405–420.PubMedGoogle Scholar
  143. 144.
    Wells SA, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994;220:237–250.PubMedCrossRefGoogle Scholar
  144. 145.
    Howe JR, Norton JA, Wells SA. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery (St. Louis) 1993;114:1070–1077.PubMedGoogle Scholar
  145. 146.
    Kallinowski F, Buhr HJ, Meybier H, Eberhardt M, Herfarth C. Medullary carcinoma of the thyroid-therapeutic strategy derived from fifteen years of experience. Surgery (St. Louis) 1993;114:491–496.PubMedGoogle Scholar
  146. 147.
    Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996;6:305–310.PubMedCrossRefGoogle Scholar
  147. 148.
    Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L. Multivarate analysis of patients with medullary thyroid carcinoma. Cancer (Phila) 1996;77:1556–1565.PubMedCrossRefGoogle Scholar
  148. 149.
    Hoie J, Jorgensen OG, Stenwig AE, Langmark F. Medullary thyroid cancer in Norway. Acta Chir Scand 1988;154:339–343.PubMedGoogle Scholar
  149. 150.
    Baudin E, Lumbroso J, Schlumberg M, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996;37:912–916.PubMedGoogle Scholar
  150. 151.
    Dorr U, Sautter-Bihl M-L, Bihl H. The contribution of somatostatin receptor scintigraphy to the diagnosis of recurrent medullary carcinoma of the thyroid. Semin Oncol 1994;21:42–45.PubMedGoogle Scholar
  151. 152.
    Juweid M, Sharkey RM, Swayne LC, Goldenberg DM. Improved selection of patients for reoperation for medullary thyroid cancer by imaging with radiolabeled anticarcinoembryonic antigen antibodies. Surgery (St. Louis) 1997;122:1156–1165.PubMedCrossRefGoogle Scholar
  152. 153.
    Chen H, Roberts JR, Ball DW, et al. Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg 1998;227:887–895.PubMedCrossRefGoogle Scholar
  153. 154.
    Moley JF, Debenedetti MK, Dilley WG, Tisell LE, Wells SA. Surgical management of patients with persistent or recurrent medullary thyroid cancer. J Intern Med 1998;243:521–526.PubMedCrossRefGoogle Scholar
  154. 155.
    Tung WS, Vesely TM, Moley JF. Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery (St. Louis) 1995;118:1024–1030.PubMedCrossRefGoogle Scholar
  155. 156.
    Tan RK, Robert K, Finley I, et al. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 1995;17:41–48.PubMedCrossRefGoogle Scholar
  156. 157.
    Tennvall J, Lundell G, Hallquist A, Wahlberg P, Wallin G, Tibblin S. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Cancer (Phila) 1994;74:1348–1354.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Ronald J. Weigel
    • 1
  1. 1.Department of SurgeryUniversity of Iowa Roy J. and Lucille A. Carver College of Medicine and University of Iowa Hospitals and ClinicsIowa CityUSA

Personalised recommendations